Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks
What it means
- What to watch: In tech, capital spending plans are the scoreboard: who is spending, on what, and whether any of it pays back.
- How the stocks are trading: $AVGO -5.48%, $MRNA -0.47% in the latest session.
- Timing: It landed over the weekend, while the market was off the clock: the change beside it is Friday's, and Monday is the first session that could react. Market holidays are not detected.
Where the stock stands
$AVGO last changed hands at $326.08, -5.48% on the session, 34% below its 52-week high of $495.00 and 12% above its low of $289.96 — in the lower part of the range. Over the year it has ranged 71% from low to high: a wide band, so a several-percent week is just a week. $MRNA last traded at $221.72, -0.47% on the session. That puts it 13% shy of its 52-week high of $254.48 and 895% clear of its low of $22.28 — in the upper part of the range. Over the year it has ranged 1042% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices.
How much coverage it is getting
In the last 30 days Wook has filed 42 stories about these names — 9 of them this week. At its 30-day pace you would expect about 10 a week, so this week is right on its usual beat. Across those stories the wording ran 17% bullish, 64% neutral and 19% bearish — mostly headline writers keeping a straight face. This one reads neutral, so it sits in step with most of the run. 20 came from Seeking Alpha; the rest came from other outlets, so this is a story more than one newsroom is chasing. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In tech and AI, follow the capex. What the largest companies spend on chips and data centers — and whether that spending shows up as revenue — moves these names more reliably than any keynote. On Wook's supply-chain scanner, Information Technology reads elevated today.
Coming up
$MRNA earnings in 6 days and $AVGO earnings in 40 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
The $AVGO page has the full chart, the filings and the valuation model behind every figure here. Comparing how two or three outlets frame the same story is the fastest way to separate the facts from the angle. Wook AI, above, can pull live figures and run the numbers on request — how far $AVGO is from its high, or how this week's coverage compares.
How this analysis was made
Seeking Alpha published it, and Wook filed it under Tech & AI. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $AVGO and $MRNA; a company mentioned in passing is tagged the same as the subject, so check which one the story is really about. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
Member research
VMware migration reduces Tottenham Hotspur's licensing fees by 85 percent https://arstechnica.com/information-technology/2026/09/vmware-migration-reduces-tottenham-hotspurs-licensing-fees-by-85-percent/